Cite
HARVARD Citation
Bauer, S. et al. (2022). Ripretinib Versus Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor After Treatment With Imatinib (INTRIGUE): A Randomized, Open-Label, Phase III Trial. Journal of clinical oncology. 40 (34), pp. 3918-3928. [Online].